Objectives: To characterize the response to current medical therapies
in children with ulcerative colitis, and to identify those factors tha
t may predict the need for colectomy. Design: Retrospective chart revi
ew at two large pediatric inflammatory bowel disease centers. Results:
We identified 171 subjects ranging in age from 1.5 to 17.7 years at d
iagnosis (mean 11.2 years). Mean follow-up was 5.1 years. Of these sub
jects, 43% had mild disease at presentation and 57% had disease that w
as classified as moderate or severe. After treatment 90% of the former
group and 81% of the latter group had resolution of symptoms by 6 mon
ths. During any subsequent yearly follow-up interval, approximately 55
% of the entire study population was symptom free, 38% had chronic int
ermittent symptoms, and 7% had continuous symptoms. A significantly lo
wer risk of colectomy was noted for those with initially mild disease
compared with those with moderate/severe disease. At I-year the risk o
f colectomy was 1% among those with mild disease versus 8% with modera
te/severe disease; at 5 years, the risk of colectomy was 9% in the mil
d disease group versus 26% in the moderate/severe disease group (p < 0
.03). Conclusions: In the majority of pediatric subjects with ulcerati
ve colitis remission is achieved in the first 6 months after therapy;
thereafter disease is inactive in about 50% of patients during any giv
en year of follow-up. Severity of disease at presentation is a signifi
cant risk factor for colectomy during the first 5 years of follow-up.
Future management protocols with more aggressive initial therapy may b
e warranted in children with moderate/severe disease.